(Reuters) – Pfizer‘s (NYSE:PFE) chief executive said on Tuesday he would prefer to wait for clarity on U.S. tax reform before engaging in any big deals in order to get a better understanding of any potential acquisition target’s value. The largest U.S. drugmaker has been under increasing pressure from investors and Wall Street to pull […]
MassDevice Earnings Roundup
AcelRx’s pain relief drug-device combo succeeds in late-stage trial
AcelRx Pharmaceuticals (NSDQ:ACRX) touted device functionality outcomes today from the Phase III trial of its Zalviso drug-device combination product. Zalviso is designed to deliver a sublingual formulation of an opioid, sufentanil, to adult patients with moderate-to-severe pain in a hospital setting using a hand-held, pre-programmed system. The device allows patients to self-administer sufentanil as often as […]
Omnicell shares surge after Q2 beat
Shares in Omnicell (NSDQ:OMCL) soared today after the company beat expectations on Wall Street with its second quarter results. The Mountain View, Calif.-based company posted profits of $837,000, or 2¢ per share, on sales of $180.9 million for the 3 months ended June 30, for sales growth of 4.6% compared with the same period last […]
Cyber attack stalls manufacturing for Merck, narrows outlook
Merck (NYSE:MRK) narrowed its full-year earnings outlook while announcing its second quarter results today. The company revealed that an international cyber attack, which hit the drugmaker in June, halted some of its manufacturing operations. While touting its second quarter financial results, Merck said that it doesn’t yet fully comprehend the magnitude of the disruption caused by […]
Tandem shares slide after Q2 sales miss
Shares in Tandem Diabetes Care (NSDQ:TNDM) fell yesterday after the medical device maker missed sales expectations but beat EPS estimates on Wall Street with its second quarter results. The San Diego, Calif.-based company posted a loss of -$21.8 million, or -44¢ per share, on sales of $21.3 million for the 3 months ended June 30, for […]
West misses on sales, beats EPS in Q2
Shares in West Pharmaceutical (NYSE:WST) fell today after the manufacturer missed sales estimates on Wall Street with its second quarter results. The Exton, Penn.-based company posted profits of $38.8 million, or 51¢ per share, on sales of $397.6 million for the 3 months ended June 30, for bottom-line loss of -13% on sales growth of […]
United Therapeutics logs Q2 beat
Shares in United Therapeutics (NSDQ:UTHR) fell today even though the biotech beat expectations on Wall Street with its second quarter results. The company recorded a net loss for the quarter and revealed that it has set aside $210 million for a possible settlement with the Dept. of Justice, according to United’s quarterly regulatory filing. The DOJ […]
Anika tops EPS estimate by 32 cents in Q2
Shares in Anika Therapeutics (NSDQ:ANIK) rose today after the orthopedics medicine company topped expectations on Wall Street with its second quarter results. The Bedford, Mass.-based company posted profits of $11.4 million, or 78¢ per share, on sales of $33.5 million for the 3 months ended June 30, for bottom-line growth of 32% on sales growth […]
Novocure misses sales, earnings estimates in Q2
Shares in Novocure (NSDQ:NVCR) fell today after the oncology company missed expectations on Wall Street with its second quarter results. The St. Helier, N.J.-based company reeled in its losses to -$21.2 million on sales of $38.4 million for the 3 months ended June 30, for bottom-line growth of 48% on sales growth of 114% compared with […]
Amgen shares fall after Q2 earnings reveal ‘bare’ pipeline
Shares in Amgen (NSDQ:AMGN) fell today even though the biotech topped expectations on Wall Street with its second quarter results. The Thousand Oaks, Calif.-based company posted profits of $2.2 million, or $2.91 per share, on sales of $5.8 billion for the 3 months ended June 30, for bottom-line growth of 15% on sales growth of […]
